A carregar...
Publicação
Novas perspetivas terapêuticas na doença de Parkinson
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.38 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A doença de Parkinson é a segunda doença neurodegenerativa mais comum sendo caracterizava pela perda de função dos neurónios dopaminérgicos e diminuição de dopamina no cérebro.
Nos últimos anos, a terapêutica sintomática tem vindo a ser otimizada recorrendo à farmacoterapia e à cirurgia. As opções terapêuticas atuais incluem intervenções farmacológicas como formulações de levodopa, agonistas dopaminérgicos, inibidores da monoamina oxidase B, inibidores da Catecol-O-metiltransferase e amantadina, além de intervenções cirúrgicas como a estimulação cerebral profunda.
Com a progressão da doença, a terapêutica convencional começa a ser menos eficaz e desenvolvem-se complicações motoras, as chamadas discinésias.
Deste modo surge a necessidade de desenvolver novas opções terapêuticas sendo que se encontram em investigação novos fármacos para tratamento dos sintomas motores e não motores, terapêuticas que diminuam a progressão da doença, compostos neuroprotetores e transplantes de células estaminais.
Com esta monografia pretende-se fazer uma revisão bibliográfica das terapêuticas atualmente disponíveis e das perspetivas futuras nomeadamente terapêuticas em investigação clínica.
Parkinson's disease is the second most common neurodegenerative disease being characterized by the loss of dopaminergic neuron function and decreased dopamine in the brain. In recent years, symptomatic therapy has been optimized using pharmacotherapy and surgery. Current therapeutic options include pharmacological interventions such as levodopa formulations, dopaminergic agonists, monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors and amantadine, and surgical interventions such as deep brain stimulation. With the progression of the disease, conventional therapy begins to be less effective and motor complications develop, the so-called dyskinesias. Therefore, the need to develop new therapeutic options arises and new drugs for the treatment of motor and non-motor symptoms, therapeutics that reduce the progression of the disease, neuroprotective compounds and stem cell transplants are being investigated. The intention of this monograph is to make a bibliographical review of currently available therapeutics and future perspectives, mainly therapeutics in clinical research.
Parkinson's disease is the second most common neurodegenerative disease being characterized by the loss of dopaminergic neuron function and decreased dopamine in the brain. In recent years, symptomatic therapy has been optimized using pharmacotherapy and surgery. Current therapeutic options include pharmacological interventions such as levodopa formulations, dopaminergic agonists, monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors and amantadine, and surgical interventions such as deep brain stimulation. With the progression of the disease, conventional therapy begins to be less effective and motor complications develop, the so-called dyskinesias. Therefore, the need to develop new therapeutic options arises and new drugs for the treatment of motor and non-motor symptoms, therapeutics that reduce the progression of the disease, neuroprotective compounds and stem cell transplants are being investigated. The intention of this monograph is to make a bibliographical review of currently available therapeutics and future perspectives, mainly therapeutics in clinical research.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2017
Palavras-chave
Doença de Parkinson Tratamento Antiparkinsónicos Ensaios clínicos Novas terapêuticas Mestrado Integrado - 2017